Terms: = Thyroid cancer AND PALB2, ENSG00000083093, 79728
10 results:
1. Genetic predisposition to differentiated thyroid cancer in the Polish population.
Borowczyk M; Sypniewski M; Szyda J; Braszka M; Ziemnicka K; Ruchała M; Oszywa M; Król ZJ; Dobosz P
Pol Arch Intern Med; 2024 Mar; 134(3):. PubMed ID: 38165228
[TBL] [Abstract] [Full Text] [Related]
2. Personalized Systemic Therapies in Hereditary cancer Syndromes.
Mastrodomenico L; Piombino C; Riccò B; Barbieri E; Venturelli M; Piacentini F; Dominici M; Cortesi L; Toss A
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980956
[TBL] [Abstract] [Full Text] [Related]
3. Pentagalloylglucose disrupts the palb2-BRCA2 interaction and potentiates tumor sensitivity to PARP inhibitor and radiotherapy.
Zeng J; Han J; Liu Z; Yu M; Li H; Yu J
Cancer Lett; 2022 Oct; 546():215851. PubMed ID: 35926819
[TBL] [Abstract] [Full Text] [Related]
4. New Perspectives on the Recurrent Monoallelic Germline Mutations of DNA Repair and Checkpoint Genes and Clinical Variability.
Sahin I; Saat H
Genet Test Mol Biomarkers; 2022 Jan; 26(1):17-25. PubMed ID: 35089076
[No Abstract] [Full Text] [Related]
5. Pancreatic Gastrinoma, Gastrointestinal Stromal Tumor (GIST), Pheochromocytoma, and Hürthle Cell Neoplasm in a Patient with Neurofibromatosis Type 1: A Case Report and Literature Review.
Arif AA; Kim PTW; Melck A; Churg A; Schwartz Z; Stuart HC
Am J Case Rep; 2021 Jan; 22():e927761. PubMed ID: 33452231
[TBL] [Abstract] [Full Text] [Related]
6. Spectrum of palb2 germline mutations and characteristics of palb2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract] [Full Text] [Related]
7. Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.
Li JY; Jing R; Wei H; Wang M; Xiaowei Q; Liu H; Jian L; Ou JH; Jiang WH; Tian FG; Sheng Y; Li HY; Xu H; Zhang RS; Guan AH; Liu K; Jiang HC; Ren Y; He JJ; Huang W; Liao N; Cai X; Ming J; Ling R; Xu Y; Hu CY; Zhang J; Guo B; Ouyang L; Shuai P; Liu Z; Zhong L; Zeng Z; Zhang T; Xuan Z; Tan X; Liang J; Pan Q; Chen L; Zhang F; Fan LJ; Zhang Y; Yang X; BoLi J; Chen C; Jiang J
Int J Cancer; 2019 Jan; 144(2):281-289. PubMed ID: 29752822
[TBL] [Abstract] [Full Text] [Related]
8. Expanding the spectrum of germline variants in cancer.
Siraj AK; Masoodi T; Bu R; Parvathareddy SK; Al-Badawi IA; Al-Sanea N; Ashari LH; Abduljabbar A; Alhomoud S; Al-Sobhi SS; Tulbah A; Ajarim D; Alzoman K; Aljuboury M; Yousef HB; Al-Dawish M; Al-Dayel F; Alkuraya FS; Al-Kuraya KS
Hum Genet; 2017 Nov; 136(11-12):1431-1444. PubMed ID: 28975465
[TBL] [Abstract] [Full Text] [Related]
9. Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients.
Xie Y; Li G; Chen M; Guo X; Tang L; Luo X; Wang S; Yi W; Dai L; Wang J
Clin Genet; 2018 Jan; 93(1):41-51. PubMed ID: 28580595
[TBL] [Abstract] [Full Text] [Related]
10. The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.
Cote S; Arcand SL; Royer R; Nolet S; Mes-Masson AM; Ghadirian P; Foulkes WD; Tischkowitz M; Narod SA; Provencher D; Tonin PN
Breast Cancer Res Treat; 2012 Jan; 131(1):333-40. PubMed ID: 21947752
[TBL] [Abstract] [Full Text] [Related]
